OncohematologyOncohematologyОнкогематология1818-83462413-4023Publishing House ABV Press105410.17650/1818-8346-2025-20-3-69-75CURRENT BASIC RESEARCH IN HEMATOLOGY AND PRACTICAL MEDICINEФУНДАМЕНТАЛЬНЫЕ ИССЛЕДОВАНИЯ В ОНКОГЕМАТОЛОГИИ И ПРАКТИЧЕСКОЙ МЕДИЦИНЕ НА СОВРЕМЕННОМ ЭТАПЕMolecular methods for assessing tumor genome instability in acute myeloid leukemiaМолекулярные методы оценки нестабильности опухолевого генома при остром миелоидном лейкозеhttps://orcid.org/0000-0001-5905-7237BessmertnyyD. K.БессмертныйД. К.
Russian Federation

Dmitry Konstantinovich Bessmertnyy

4 Novyy Zykovskiy Proezd, Moscow 125167

Дмитрий Константинович Бессмертный

125167 Москва, Новый Зыковский пр-д, 4

dmitry_bessmertnyy@mail.ruhttps://orcid.org/0000-0003-0934-6094FidarovaZ. T.ФидароваЗ. Т.
Russian Federation

National Medical Research Center for Hematology, Ministry of Health of Russia

125167 Москва, Новый Зыковский пр-д, 4

National Medical Research Center for Hematology, Ministry of Health of RussiaФГБУ «Национальный медицинский исследовательский центр гематологии» Минздрава России1109202520369751109202511092025https://oncohematology.abvpress.ru/ongm/article/view/1054

Laboratory diagnostics of acute myeloid leukemia enables accurate risk stratification of patients into prognostic groups according to modern classifications and facilitates personalized treatment selection. However, relapses and refractory forms still occur within each prognostic group. Some cytogenetic and molecular aberrations cannot be detected using standard diagnostic methods. Modern advanced laboratory techniques may uncover the mechanisms of tumor refractoriness and identify novel targets for therapy, which could improve acute myeloid leukemia diagnostics and patient prognosis.

Лабораторная диагностика острых миелоидных лейкозов позволяет грамотно стратифицировать больных на группы риска согласно современным классификациям и подобрать персонифицированное лечение. Однако в каждой группе прогноза все равно развиваются рецидивы заболевания и констатируются рефрактерные формы. Некоторые цитогенетические и молекулярные аберрации не могут быть обнаружены с помощью стандартных методов диагностики. Новые, современные лабораторные методы потенциально могут выявить механизмы рефрактерности опухоли, а также новые мишени для таргетной терапии, что может улучшить диагностику и прогноз больных острым миелоидным лейкозом.

acute myeloid leukemiagenomic instabilitymolecular diagnosis of acute myeloid leukemiaострый миелоидный лейкознестабильность геномамолекулярная диагностика острого миелоидного лейкозаDöhner H., Wei A.H., Appelbaum F.R. et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 2022;140(12):1345–77. DOI: 10.1182/blood.2022016867Bullinger L., Krönke J., Schön C. et al. Identification of acquired copy number alterations and uniparental disomies in cytogenetically normal acute myeloid leukemia using high-resolution singlenucleotide polymorphism analysis. Leukemia 2010;24(2):438–49. DOI: 10.1038/leu.2009.263Khoury J.D., Solary E., Abla O. et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia 2022;36(7):1703–19. DOI: 10.1038/s41375-022-01613-1Tallman M.S., Wang E.S., Altman J.K. et al. Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2019;17(6):721–49. DOI: 10.6004/jnccn.2019.0028Akkari Y.M.N., Baughn L.B., Dubuc A.M. et al. Guiding the global evolution of cytogenetic testing for hematologic malignancies. Blood 2022;139(15):2273–84. DOI: 10.1182/blood.2021014309Lo M.Y., Tsai C.H., Kuo Y.Y. et al. Prognostic relevance of adult acute myeloid leukemia patients according to the 2022 European Leukemianet Risk Stratification. Blood 2022;140(Suppl 1):130–1. DOI: 10.1182/blood-2022-168522Li H., Zimmerman S.E., Weyemi U. Genomic instability and metabolism in cancer. Int Rev Cell Mol Biol 2021;364:241–65. DOI: 10.1016/BS.IRCMB.2021.05.004Targa A., Rancati G. Cancer: a CINful evolution. Curr Opin Cell Biol 2018;52:136–44. DOI: 10.1016/j.ceb.2018.03.007Bakhoum S.F., Kabeche L., Murnane J.P. et al. DNA-damage response during mitosis induces whole-chromosome missegregation. Cancer Discov 2014;4(11):1281–9. DOI: 10.1158/2159-8290.CD-14-0403Venkatesan S., Natarajan A.T., Hande M.P. Chromosomal instability – mechanisms and consequences. Mutat Res Genet Toxicol Environ Mutagen 2015;793:176–84. DOI: 10.1016/J.MRGENTOX.2015.08.008Hoevenaar W.H.M., Janssen A., Quirindongo A.I. et al. Degree and site of chromosomal instability define its oncogenic potential. Nat Commun 2020;11(1):1501. DOI: 10.1038/s41467-020-15279-9Compton D.A. Mechanisms of aneuploidy. Curr Opin Cell Biol 2011;23(1):109–13. DOI: 10.1016/j.ceb.2010.08.007Hitzler J.K., Zipursky A. Origins of leukaemia in children with Down syndrome. Nat Rev Cancer 2005;5(1):11–20. DOI: 10.1038/nrc1525Thompson S.L., Compton D.A. Proliferation of aneuploid human cells is limited by a p53-dependent mechanism. J Cell Biol 2010;188(3):369–81. DOI: 10.1083/jcb.200905057Lal R., Lind K., Heitzer E. et al. Somatic TP53 mutations characterize preleukemic stem cells in acute myeloid leukemia. Blood 2017;129(18):2587–91. DOI: 10.1182/blood-2016-11-751008Fontana M.C., Marconi G., Feenstra J.D.M. et al. Chromothripsis in acute myeloid leukemia: biological features and impact on survival. Leukemia 2018;32(7):1609–20. DOI: 10.1038/s41375-018-0035-yRausch T., Jones D.T., Zapatka M. et al. Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell 2012;148(1–2):59–71. DOI: 10.1016/j.cell.2011.12.013Qiu Z., Zhang Z., Roschke A. et al. Generation of gross chromosomal rearrangements by a single engineered DNA double strand break. Sci Rep 2017;7(1):43156. DOI: 10.1038/srep43156Khan F.A., Ali S.O. Physiological roles of DNA double-strand breaks. J Nucleic Acids 2017;2017:6439169. DOI: 10.1155/2017/6439169Jacoby M.A., De Jesus Pizarro R.E., Shao J. et al. The DNA double-strand break response is abnormal in myeloblasts from patients with therapy-related acute myeloid leukemia. Leukemia 2014;28(6):1242–51. DOI: 10.1038/leu.2013.368De Lange T. Shelterin: the protein complex that shapes and safeguards human telomeres. Genes Dev 2005;19(18):2100–10. DOI: 10.1101/gad.1346005Mosrati M.A., Willander K., Falk I.J. et al. Association between TERT promoter polymorphisms and acute myeloid leukemia risk and prognosis. Oncotarget 2015;6(28):25109–20. DOI: 10.18632/oncotarget.4668Yan S., Han B., Wu Y. et al. Telomerase gene mutation screening and telomere overhang detection in Chinese patients with acute myeloid leukemia. Leuk Lymphoma 2013;54(7):1437–41. DOI: 10.3109/10428194.2012.729834Sun Y., Chen B.-R., Deshpande A. Epigenetic regulators in the development, maintenance, and therapeutic targeting of acute myeloid leukemia. Front Oncol 2018;8:41. DOI: 10.3389/fonc.2018.00041Wang J., He N., Wang R. et al. Analysis of TET2 and EZH2 gene functions in chromosome instability in acute myeloid leukemia. Sci Rep 2020;10(1):2706. DOI: 10.1038/s41598-020-59365-wMrózek K., Eisfeld A.K., Kohlschmidt J. et al. Complex karyotype in de novo acute myeloid leukemia: typical and atypical subtypes differ molecularly and clinically. Leukemia 2019;33(7):1620–34. DOI: 10.1038/s41375-019-0390-3Forghieri F., Comoli P., Marasca R. et al. Minimal/measurable residual disease monitoring in NPM1-mutated acute myeloid leukemia: a clinical viewpoint and perspectives. Int J Mol Sci 2018;19(11):3492. DOI: 10.3390/ijms19113492Hause R.J., Pritchard C.C., Shendure J., Salipante S.J. Classification and characterization of microsatellite instability across 18 cancer types. Nat Med 2017;22(11):1342–50. DOI: 10.1038/nm.4191Nomdedéu J.F., Perea G., Estivill C. et al. Microsatellite instability is not an uncommon finding in adult de novo acute myeloid leukemia. Ann Hematol 2005;84(6):368–75. DOI: 10.1007/s00277-005-1035-3El Hussein S., Daver N., Liu J.L. et al. Microsatellite instability assessment by immunohistochemistry in acute myeloid leukemia: a reappraisal and review of the literature. Clin Lymphoma Myeloma Leuk 2022;22(6):e386–91. DOI: 10.1016/j.clml.2021.12.004Bates S.E. Classical cytogenetics: karyotyping techniques. Methods Mol Biol 2011;767:177–90. DOI: 10.1007/978-1-61779-201-4_13Bayani J., Squire J.A. Fluorescence in situ hybridization (FISH). Curr Protoc Cell Biol 2004;22:Unit22.4. DOI: 10.1002/0471143030.cb2204s23Hart S.M., Foroni L. Core binding factor genes and human leukemia. Haematologica 2002;87(12):1307–23.Mrózek K., Heerema N.A., Bloomfield C.D. Cytogenetics in acute leukemia. Blood Rev 2004;18(2):115–36. DOI: 10.1016/S0268-960X(03)00040-7Marcucci G., Mrózek K., Ruppert A.S. et al. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. J Clin Oncol 2005;23(24):5705–17. DOI: 10.1200/JCO.2005.15.610Grimwade D., Walker H., Harrison G. et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001;98(5):1312–20. DOI: 10.1182/blood.v98.5.1312Weinberg O.K., Siddon A., Madanat Y.F. et al. TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML. Blood Adv 2022;6(9):2847–53. DOI: 10.1182/bloodadvances.2021006239Meyer C., Burmeister T., Gröger D. et al. The MLL recombinome of acute leukemias in 2017. Leukemia 2018;32(2):273–84. DOI: 10.1038/leu.2017.213Lugthart S., Gröschel S., Beverloo H.B. et al. Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3) (q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia. J Clin Oncol 2010;28(24):3890–8. DOI: 10.1200/JCO.2010.29.2771Wang J., Zheng J., Lee E.E. et al. A cloud-based resource for genome coordinate-based exploration and large-scale analysis of chromosome aberrations and gene fusions in cancer. Genes Chromosomes Cancer 2023;62(8):441–8. DOI: 10.1002/gcc.23128Slovak M.L., Gundacker H., Bloomfield C.D. et al. A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare “poor prognosis” myeloid malignancies. Leukemia 2006;20(7):1295–7. DOI: 10.1038/sj.leu.2404233Garibyan L., Avashia N. Polymerase chain reaction. J Invest Dermatol 2013;133(3):1–4. DOI: 10.1038/jid.2013.1Lorenz T.C. Polymerase chain reaction: basic protocol plus troubleshooting and optimization strategies. J Vis Exp 2012;(63):e3998. DOI: 10.3791/3998Ossenkoppele G., Schuurhuis G.J. MRD in AML: does it already guide therapy decision-making? Hematology Am Soc Hematol Educ Program 2016;2016(1):356–65. DOI: 10.1182/asheducation-2016.1.356Lobanova T.I., Galtseva I.V., Parovichnikova E.N. Minimal residual disease assesment in patients with acute myeloid leukemia by multicolour flow cytometry (literature review). Onkogematologiya = Oncohematology 2018;13(1):83–102. (In Russ.). DOI: 10.17650/1818-8346-2018-13-1-83-102Лобанова Т.И., Гальцева И.В., Паровичникова Е.Н. Исследование минимальной остаточной болезни у пациентов с острыми миелоидными лейкозами методом многоцветной проточной цитофлуориметрии (обзор литературы). Онкогематология 2018;13(1):83–102. DOI: 10.17650/1818-8346-2018-13-1-83-102Kashlakova A.I., Parovichnikova E.N., Biderman B.V. et al. Nextgeneration sequencing-based molecular genetic profiling in adults with acute myeloid leukaemia. Gematologiya i transfuziologiya = Russian Journal of Hematology and Transfusiology 2020;65(4): 444–59. (In Russ.). DOI: 10.35754/0234-5730-2020-65-4-444-459Кашлакова А.И., Паровичникова Е.Н., Бидерман Б.В. и др. Определение молекулярно-генетического профиля у взрослых больных острыми миелоидными лейкозами методом секвенирования нового поколения. Гематология и трансфузиология 2020;65(4):444–59. DOI: 10.35754/0234-5730-2020-65-4-444-459Mareschal S., Palau A., Lindberg J. et al. Challenging conventional karyotyping by next-generation karyotyping in 281 intensively treated patients with AML. Blood Adv 2021;5(4):1003–16. DOI: 10.1182/bloodadvances.2020002517Höllein A., Nadarajah N., Meggendorfer M. et al. Molecular characterization of AML with RUNX1‐RUNX1T1 at diagnosis and relapse reveals net loss of co‐mutations. Hemasphere 2019;3(1):e178. DOI: 10.1097/HS9.0000000000000178Morita K., Wang F., Jahn K. et al. Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. Nat Commun 2020;11(1):5327. DOI: 10.1038/s41467-020-19119-8Kashlakova A.I., Biderman B.V., Parovichnikova E.N. Clonal hematopoiesis and acute myeloid leukemia. Onkogematologiya = Oncohematology 2023;18(3):92–101. (In Russ.). DOI: 10.17650/1818-8346-2023-18-3-92-101Кашлакова А.И., Бидерман Б.В., Паровичникова Е.Н. Клональное кроветворение и острые миелоидные лейкозы. Онкогематология 2023;18(3):92–101. DOI: 10.17650/1818-8346-2023-18-3-92-101Falini B., Brunetti L., Sportoletti P., Martelli M.P. NPM1-mutated acute myeloid leukemia: from bench to bedside. Blood 2020;136(15):1707–21. DOI: 10.1182/blood.2019004226Gorello P., Cazzaniga G., Alberti F. et al. Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations. Leukemia 2006;20(6):1103–8. DOI: 10.1038/sj.leu.2404149Tiong I.S., Dillon R., Ivey A. et al. The natural history of NPM1MUT measurable residual disease (MRD) positivity after completion of chemotherapy in acute myeloid leukemia (AML). Blood 2020;136(Suppl 1):25–7. DOI: 10.1182/blood-2020-140296Kottaridis P.D., Gale R.E., Frew M.E. et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001;98(6):1752–9. DOI: 10.1182/blood.V98.6.1752Lin M.T., Tseng L.H., Beierl K. et al. Tandem Duplication PCR. Diagn Mol Pathol 2013;22(3):149–55. DOI: 10.1097/PDM.0b013e31828308a1He R., Devine D.J., Tu Z.J. et al. Hybridization capture-based next generation sequencing reliably detects FLT3 mutations and classifies FLT3-internal tandem duplication allelic ratio in acute myeloid leukemia: a comparative study to standard fragment analysis. Mod Pathol 2020;33(3):334–43. DOI: 10.1038/s41379-019-0359-9Schlenk R.F., Weber D., Fiedler W. et al. Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD. Blood 2019;133(8): 840–51. DOI: 10.1182/blood-2018-08-869453Batzir N.A., Shohat M., Maya I. Chromosomal microarray analysis (CMA) a clinical diagnostic tool in the prenatal and postnatal settings. Pediatr Endocrinol Rev 2015;13(1):448–54.Zhang C., Cerveira E., Romanovitch M., Zhu Q. Array-based comparative genomic hybridization (aCGH). Methods Mol Biol 2017;1541:167–79. DOI: 10.1007/978-1-4939-6703-2_15Grimwade D., Mrózek K. Diagnostic and prognostic value of cytogenetics in acute myeloid leukemia. Hematol Oncol Clin North Am 2011;25(6):1135–61, vii. DOI: 10.1016/j.hoc.2011.09.018Ibáñez M., Such E., Onecha E. et al. Analysis of SNP array abnormalities in patients with de novo acute myeloid leukemia with normal karyotype. Sci Rep 2020;10(1):5904. DOI: 10.1038/s41598-020-61589-9Walker C.J., Kohlschmidt J., Eisfeld A.K. et al. Genetic characterization and prognostic relevance of acquired uniparental disomies in cytogenetically normal acute myeloid leukemia. Clin Cancer Res 2019;25(21):6524–31. DOI: 10.1158/1078-0432.CCR-19-0725Ronaghy A., Yang R.K., Khoury J.D., Kanagal-Shamanna R. Clinical applications of chromosomal microarray testing in myeloid malignancies. Curr Hematol Malig Rep 2020;15(3):194–202. DOI: 10.1007/s11899-020-00578-1Gronseth C.M., McElhone S.E., Storer B.E. et al. Prognostic significance of acquired copy-neutral loss of heterozygosity in acute myeloid leukemia. Cancer 2015;121(17):2900–8. DOI: 10.1002/CNCR.29475Mak A.C., Lai Y.Y., Lam E.T. et al. Genome-wide structural variation detection by genome mapping on nanochannel arrays. Genetics 2016;202(1):351–62. DOI: 10.1534/genetics.115.183483Levy B., Baughn L.B., Akkari Y. et al. Optical genome mapping in acute myeloid leukemia: a multicenter evaluation. Blood Adv 2023;7(7):1297–307. DOI: 10.1182/bloodadvances.2022007583Balducci E., Kaltenbach S., Villarese P. et al. Optical genome mapping refines cytogenetic diagnostics, prognostic stratification and provides new molecular insights in adult MDS/AML patients. Blood Cancer J 2022;12(9):126. DOI: 10.1038/s41408-022-00718-1